Therefore, we suggest that CD34-MVD should be routinely detected in patients with lung adenocarcinoma after operation, and the patients with low CD34-MVD should be examined and evaluated for tumor recurrence more frequently during the follow-up period. This evidence concerns the gene CD34 and lung adenocarcinoma.